StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report issued on Wednesday morning. The brokerage issued a sell rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Maxim Group cut Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Moleculin Biotech in a research note on Monday.

Moleculin Biotech Stock Up 7.4 %

NASDAQ:MBRX opened at $1.16 on Wednesday. The stock has a 50 day moving average price of $1.50 and a 200 day moving average price of $2.13. Moleculin Biotech has a one year low of $0.40 and a one year high of $10.35.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.